Duality Biologics (Suzhou) Co., Ltd.

MAINZ, Germany, October 21, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2024 on Monday, November 4, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this link. Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company’s website at www.BioNTech.com. A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call. About BioNTech Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Biotheus, DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron. For more information, please visit www.BioNTech.com. CONTACTS Investor RelationsMichael HorowiczInvestors@biontech.de Media RelationsJasmina Alatovic+49 (0)6131 9084 1513Media@biontech.de

Provides updates on BioNTech’s strategy to scale and deploy AI-capabilities across the immunotherapy pipelineHighlights InstaDeep’s new near exascale supercomputer, Kyber, with the aim of enabling BioNTech to compute at scaleUnveils novel AI Bayesian Flow Network (“BFN”) models for protein sequence generationHighlights progress in deploying AI across BioNTech’s immunotherapy pipeline, including in immunohistochemistry, DNA/RNA sequencing, proteomics, protein design, and lab functional validation LONDON, United Kingdom, October 1, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), alongside its artificial intelligence (“AI”) subsidiary InstaDeep Ltd. (“InstaDeep”), today presents an overview of its AI approach during an edition of the Company’s Innovation Series, AI Day. “At BioNTech, we are at the forefront of integrating advanced AI to revolutionize individualized medicine. With our in-house AI specialist, InstaDeep, we are pioneering the use of artificial intelligence to develop personalized vaccines and targeted therapies,” said Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “By introducing state-of-the-art technologies such as our BFN generative protein model and incorporating AI capabilities across our immunotherapy pipeline, we are unlocking the full potential of AI to deliver innovative vaccines and cancer treatments to patients worldwide”. “BioNTech and InstaDeep, as a biotechnology powerhouse with a dedicated AI unit, are uniquely positioned at the intersection of biotechnology and AI,” said Karim Beguir, CEO and Co-Founder of InstaDeep, a BioNTech company. “Working closely together and combining expertise from AI research, high performance computing, software and biology is accelerating innovation. A key focus of this collaboration is our DeepChain™ multiomics design platform. DeepChain™ is now open for external partnerships, after successful application to several projects, including the mRNA-encoded antibody RiboMab™ platform. We are excited to harness breakthroughs in both AI and biotechnology synergistically.’’ As part of the event, BioNTech will showcase the Company’s approach to AI capability scaling and deployment across BioNTech’s pipeline. These updates will cover the introduction of a new near exascale supercomputer, the launch of a novel BFN generative model, and multiple updates on the deployment of AI across BioNTech’s immunotherapy pipeline. The live webcast of the event will be available via this link and will begin at 3:00 pm CEST (2:00 pm BST, 9:00 am EDT). A replay of the webcast will be available shortly after the event’s conclusion and archived on BioNTech’s website for one year. About BioNTechBiopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Biotheus, DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron. For more information, please visit www.BioNTech.com. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning the impact of, and expectations regarding, BioNTech’s AI capabilities and future research and development activities. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events, and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development,; competition from other product candidates BioNTech’s and its counterparties’ ability to manage and source necessary energy resources; BioNTech’s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech’s third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; BioNTech’s ability to manage its development; regulatory developments in the United States and other countries; BioNTech’s ability to effectively scale its production capabilities and manufacture its products and product candidates; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time. You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended June 30, 2024 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. CONTACTS Investor RelationsMichael HorowiczInvestors@biontech.de Media RelationsJasmina Alatovic+49 (0)6131 9084 1513Media@biontech.de

One of the original AI-driven drug discovery and development biotechs has let its plans to list on the Hong Kong stock exchange lapse for the second time in as many years. Insilico Medicine, a clinical-stage startup that has raised more than $400 million in its first decade, will not move forward with the proposed listing at this time, according to an update from the HKEX site. It filed for the IPO in March. Applications on the exchange lapse after two quarters of no action. The move comes as multiple biotech startups have lined up IPOs stateside . Earlier Thursday, BioAge went public on the Nasdaq . Insilico would have been the second AI-driven biotech to land on the HKEX this year, following Chinese company XtalPi’s $115 million listing earlier this summer. Meanwhile, another drug developer, Sichuan Biokin Pharmaceutical, filed this month for a listing on the exchange with an eye toward a $500 million raise, Bloomberg News reported in July. Meanwhile, BioNTech- and BeiGene-partnered Duality Biologics also plans to list on the Hong Kong exchange. This month, Insilico presented some Phase 2a data on its idiopathic pulmonary fibrosis drug candidate, but multiple questions remain about the experimental medicine’s efficacy and future plans. “Of course we want to raise, but we also want to raise at the right valuation,” CEO Alex Zhavoronkov told Endpoints News during an interview about last week’s data readout. “And we want to raise when the market is in the right position. Because currently, those IPOs of quote, unquote, AI drug discovery companies that may not have been ready at that time — and they either in-license the drugs or start with very, very old targets and just repositioned traditional biotech as AI — many of them have failed, right? And they are trading at cash or sometimes below cash. So you don’t want to go out when something like that is happening.” Insilico had filed for a listing on the HKEX last year, as well, but did not follow through. It had also reportedly confidentially filed for a US listing in fall 2021, according to a Bloomberg report from November of that year, citing anonymous sources. The company then disclosed a $60 million Series D in June 2022. The Series D would fuel the biotech for at least three years, Zhavoronkov told Endpoints at the time of the 2022 financing. “You can see that some of the biotech companies out there are slaughtered,” Zhavoronkov said. “Every day I’m being approached by an AI company because they are running out of cash. And so right now you can see the clear winners are crystallized, right?” The company was one of the early biotechs to tout artificial intelligence’s role in the future of drug discovery. Many have emerged since, and initial clinical trials have been tough . New power players have come to the fore in recent years, including a more than $1 billion bet on Xaira Therapeutics , which marked one of the largest biotech startup launches in history. Insilico had $177 million in cash and equivalents at the end of 2023, according to its March IPO filing. While that sounds like a large coffer, the biotech is entering the costly stages of human trials. It spent $97 million on R&D in 2023, a $19 million year-over-year increase, according to its IPO paperwork. The biotech is in early- and mid-stage clinical trials in China, New Zealand and the US for idiopathic pulmonary fibrosis , various solid tumors , inflammatory bowel disease and anemia of chronic kidney disease, among other areas. It has plans for testing in multiple additional diseases later this year and in 2025. Sanofi and Fosun Pharma are among Insilico’s partners, and it has out-licensing deals with Menarini’s Stemline and Exelixis . Insilico recently moved its headquarters from New York to the Boston area, 10 years after originally setting up shop in Baltimore. The AI-driven firm will retain a site in New York and also has offices and labs in Montreal, Hong Kong, Abu Dhabi, Taipei, Shanghai and Suzhou. It had 356 employees and consultants, 81% dedicated to R&D, according to its March IPO filing. Zhavoronkov holds the largest amount of shares in Insilico at 10.32%, according to the March IPO prospectus. Additional large owners include Palace Investments, Qiming Venture Partners, Warburg Pincus and Aramco Ventures, among others. Its executive team also includes former GSK China R&D vet Feng Ren , who is CSO and co-CEO. Former Eli Lilly associate VP Sujata Rao is chief medical officer, former WuXi Biologics SVP Michelle Chen is business chief and Alex Aliper is president. Max Gelman contributed reporting.